Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.97 |
| ▸ | BTK | Q06187 | 3/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 2/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9202451 | 0.98 | HTT (1.00) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL9205088 | 0.95 | HTT (0.94) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL797546 | 0.92 | LMNA (0.88) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL30320047 | 0.91 | LMNA (0.82) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL3451451 | 0.78 | LMNA (0.63) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL16146912 | 0.78 | LMNA (0.63) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL6643412 | 0.78 | LMNA (0.65) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL1803031 | 0.78 | LMNA (0.63) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL797051 | 0.78 | LMNA (0.63) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL16146166 | 0.78 | LMNA (0.63) | LMNAHTTPKMHSD17B10PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| EP-1616034-A4 | ACYL- PHOSPHATE AND PHOSPHONATE PROBES AND METHODS OF THEIR SYNTHESIS AND USE IN PROTEOMIC ANALYSIS | ACTIVX BIOSCIENCES INC (US) | 2008-12-03 | — | — | EP | claimed |
| EP-1616034-A2 | ACYL- PHOSPHATE AND PHOSPHONATE PROBES AND METHODS OF THEIR SYNTHESIS AND USE IN PROTEOMIC ANALYSIS | Activx Biosciences, Inc. (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004090154-A2 | ACYL- PHOSPHATE AND PHOSPHONATE PROBES AND METHODS OF THEIR SYNTHESIS AND USE IN PROTEOMIC ANALYSIS | ACTIVX BIOSCIENCES, INC. (US) | 2004-10-21 | — | — | WO | claimed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-11041207-B2 | Method for predicting a subject's response to valproic acid therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-06-22 | — | — | US | disclosed |
| CN-108703970-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2018-10-26 | — | — | CN | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| US-20130231307-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2616474-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | Centre National De La Recherche Scientifique (FR) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012034719-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-22 | — | — | WO | disclosed |
| EP-0286425-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1995-01-11 | — | — | EP | disclosed |
| US-5185437-A | 6-substituted 2',3'-dideoxypurine nucleosides; treatment for human immunodeficiency virus and heptatis b virus | BURROUGHS WELLCOME CO. (US) | 1993-02-09 | — | — | US | disclosed |
| US-5068320-A | 2-amino-6-(cyclopropylamino)purine-9-β-D-2',3'-dideoxyribofuranoside and its pharmaceutically acceptable salts | BURROUGHS WELLCOME CO. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0421819-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0286425-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | LMNA 599/4885HTT 3291/4885PKM 91/4885 |
| US-20130231307-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | PNP, TYMP, EIF2AK2 | LMNA 3155/4885HTT 3727/4885PKM 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.